CTIX News 08/10/2014 18:52:36 $CTIX No kidding. Went to

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
CTIX News 08/10/2014 18:52:36 $CTIX
No kidding. Went to church for a few hours and what the heck has been going on around here? Now we have Dr george too? Good grief..............
Not criticizing you by any means but it. Was just ten eleven twelve that emailed df for a friend in Pennsylvania that found out about wait list. Was confirmed by your cited email and a poster on a. Breast cancer board.

Tomorrow market is open and we can get back to business of share price. Thank goodness

Gov
Check asco it was ten eom gov
That guest should be careful for what they wish for...... We are on borrowed time here in FL, eight years without a direct hit, at some point that will change. While weather is fascinating, no desire to see a Cat 2 or higher up close, I would be long gone before that if I lived right on the coast and in the storm surge zone....
I did not mean to say in absolutes. I was simply trying to point out the significance of multiple cycles. Dr. Jorgensen also stressed this point at Biotech Showcase.

Quote:
There are so many factors at play that it is ridiculous at this point to speak in absolutes.


Actually there is a waiting list for the Kevetrin trial. A poster here called DF and was told about the waiting list. Dr. Menon also said he does not expect a shortage of patients. Of course not everyone qualifies. Karen’s friend is an example.

Quote:
If things were so black and white there would be many more patients lining up for Kevetrin and many more investors as well, which there aren't.


As one guest put it, I paid for a full hurricane and this is all I got?

Big Island didn't fair as well as Oahu. Sadly, the occupants of a car perished trying to reach safety crossing a storm swollen stream.

Quote:
BK I hope you faired well in the recent storms in Hawaii,

Good Luck and GOD Bless......BUT pleeeeeease...enough already...

http://www.youtube.com/watch?v=d8cpkwPAbY0

GIDDDDDDDY UP & GOOOOOOOOOOOOOOOOOOOOOOO CTIX !
I am pretty sure the K trial starting dosage was 10mg/m2, not 15mg/kg
Hi rnn256, I agree with your last paragraph, we do need to take some of these guidelines with a grain of salt. If converting a mouse dose to a HED was simple in terms of determining what the anticipated efficacy should be when comparing efficacy in the mouse to humans, there would be would be few drug failures. Obviously that is not the case. The allometric scaling approach has limitations on the types of drug being tested and factors such as how highly protein bound the drug it, biliary vs renal excretion mechanisms and binding sites all come in to play as noted in the Sharma and McNeill paper.

At the end of the day we are placing faith in Dr. Menon's judgment and that's ok with me. He has a wonderful track record and I think his veterinary background also provides him with valuable insight when it comes to drug effects on differing species. My gut feeling tells me he is a driven "lab geek" who has special clinical skills (the lab geek reference is meant as a compliment). Hopefully we will have our confirmation in early 2015 (although another cohort or 2 would be fine with me). In closing perhaps what the underlying tone of this thread is defining what realistic expectations are. Speaking for myself, I cringe when I see some saying Kevetrin will be the cure for Cancer. While I would love to be wrong, I think it more accurately should be said that Kevetrin will cure some of cancer, very big difference but still a fabulous outcome that we all want at the end of the day for those suffering with cancer. I hope my comments today were not viewed as being a doubting Debby or negative in my hopes for Kevetrin. Time to go finish mowing my lawn in between the afternoon showers in FL. BK I hope you faired well in the recent storms in Hawaii, many years ago my sister lived on Oahu and I spent a summer there between by junior and senior years in high school (Rainbow Towers, Waikiki, I won't say how long ago.....) lots of beauty there.


George, just wondering why you repeatedly bring up the number 200 mg/kg but ignore Dr. Menon’s opinion that the efficacy range is 100-200 mg/m2 in humans? You think K will be a breakthrough drug, but the current dosage is nowhere near your magic number of 200 mg/kg. How is it possible then? Dr. Menon said he expects the MTD to be near, and yes, he told some posters in person after a conference. I tend to believe him because he has been right so far. He said P should convert to abacavir and he was right. He said MTD should be cohort 5-9 and he was right again. If DLT occurs in cohort 8 (not likely at this point) then cohort 9 is MTD. Whether you believe him or not is up to you of course.

Quote:
The dosage in humans is no where near 200 mg/kg.

Thank you all. So informative . c ya at 100 a share. Eom
This is by far the BEST board on this pathetic website ...eom
Based in the xenograft models K (200 mg/kg) proved to be more effective than paclitaxel (22 mg/Kg)

With regards to paclitaxel dosing:

Activity for paclitaxel 135 mg/m2 and 200 mg/m2 by 1-hour infusion every 3 weeks in patients with NSCLC, with minimal myelosuppression and the suggestion of a dose-response relationship, has been reported. In November 1994, we initiated a phase II trial in patients with advanced, measurable, chemotherapy-naive NSCLC using paclitaxel 175 mg/m2 given in 1 hour, and carboplatin dosed to a fixed target area under the concentration-time curve of 7.5 every 3 weeks. In the absence of grade 4 myelosuppression, paclitaxel was escalated on an intrapatient basis by 35 mg/m2 per cycle to a maximum dose of 280 mg/m2 by cycle 4.

Kevetrin:
The dosing was been increased approximately 33 percent from the seventh cohort to 215 mg/m2.

At the end of day models are just guidelines to be taken with a grain of salt and maybe because of K very short 1/2 life and non-genotoxic properties this will allow it to dose patients more frequently, maybe the MTD is still far away . But I see your point with regards to efficacy vs current dosing escalation.
That is a sweet looking flag on the 3 year chart. Thanks for that visual. Breakout to the upside could be imminent and swift.
I'm done with you, seeker of truth. What a load of crap. Nothing like ignoring all evidence to the contrary.
Your post is not clear.

Please, repost in a more coherent form.

What exactly are you saying about how the results from the preclinical posters for animal studies performed a 200 mg/kg relate to the current 215 mg/sq m human phase I trial. Should we expect similar results?

What results do you expect from the current 215 mg/sq m dose in humans???

Good luck and GOD bless,

George
I don't know if there's anything untruthful in that post and I don't care.

Any value to the topics you introduced ended after your first two or three posts.

At this point, we really don't care anymore. Just... let... it... go.......
Yes, the assumption that human equivalency in tumor growth delay is simply dependent on a 200 mg/kg dose shown in mouse studies, and using that number as the benchmark for expectations. That is not truthful.
Quote:

Kevetrin may be a good combination with chemotherapy and/or radiation.

The dosage in humans is no where near 200 mg/kg.

Stop the bullshit challenges. I'm only pointing out that using body weight, or even BSA, for converting to HED for other than starting dose is much more complicated than using Baur's simple formula. The misapplication of that simplistic conversion has caused much confusion over the years. The article I referenced points to exactly that problem.

I challenge you, since you are a seeker of truth, to enter a Ph.D. program and seek the truth regarding formulations for HED. It's a wide open field of study.

Please note that I am ignoring your insult "Now that you seem to be willing to logically and intelligently pursue the truth..."
Can anyone find anything untruthful in this post???

Do not expect miracles from Kevetrin

Limit your expectations for the Kevetrin Phase I trial to the realistic goal of finding a safe MTD that shows promise when used in combination with chemotherapy and/ or radiation.

For example, Avastin was not approved until it showed promise when used in combination with chemotherapy for colorectal cancer. Avastin has since made $BILLIONS in sales and is used as a treatment in combination with chemotherapy and/or radiation for a wide variety of cancers. Expect similar results for Kevetrin.

http://www.fda.gov/newsevents/newsroom/pressa...108252.htm

Kevetrin may be a good combination with chemotherapy and/or radiation.

The dosage in humans is no where near 200 mg/kg.

http://cellceutix.com/wp-content/uploads/pdfs...-11x17.pdf

http://cellceutix.com/wp-content/uploads/pdfs...0FINAL.pdf

Good luck and GOD bless,

George

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BC Mosaic App Store Unlocks New Tools for Researchers

Updated Category News Views 2

Unleashing Innovation Through Specialized Apps Oh boy, it's about time someone shook things up in the research game. BC Platforms has rolled out the BC Mosaic App Store, a move that's got research types buzzing from Zurich to... well, anywhere healthcare pokes its head. These guys aren't just throwing out some generic, run-of-the-mill tools. No sir, they've created a...

Continue Reading
Broadridge Expands Tokenization with G7 Securities

Updated Category News Views 9

Broadridge Takes a Big Step with G7 Integration Broadridge Financial Solutions is pulling no punches with its latest move—integrating G7 securities into its Distributed Ledger Repo (DLR) network. This isn't your average fintech maneuver; it's a heavyweight shift intended to redefine the way global financing and collateral markets work. Tokenized Repo: More Than Just a...

Continue Reading
Skanska's $57M Deal to Transform Del Mar Traffic

Updated Category News Views 5

A Roadway Overhaul in Del Mar A cool $57 million. That’s the ticket Skanska bought to scoop up the El Camino Real project in Del Mar, California. Think of it as a road facelift, a necessary one—it includes bulking up the corridor to four lanes and swapping in a spanking new San Dieguito River Bridge, taking the place of an old rascal that's been around for 84 years....

Continue Reading
Fibocom's RU311: Navigating 5G's Mid-Tier Maze

Updated Category News Views 4

Cracking Open the RU311 Phenomenon Technology must evolve with purpose. This time around, Fibocom's RU311 module series steps up to the plate, delivering a tailored solution in the 5G landscape for the mid-tier IoT devices that need more than just speed. Beyond Raw Bandwidth: What Really Matters Plenty of folks out there still chase the elusive thrill of higher speeds as...

Continue Reading
Royal Mint Ventures Into the Final Frontier with Star Trek Coins

Updated Category News Views 1

A Cosmic Coin Collection for the Ages The Royal Mint has stepped boldly into a realm where no coin has gone before—celebrating six decades of Star Trek with two new collectable 50p coins. For Star Trek fans who’ve followed the Enterprise to the furthest reaches of the galaxy, these coins aren’t just chump change—they’re keepsakes that capture a piece of sci-fi...

Continue Reading
stackArmor Secures FedRAMP High: A Strategic Milestone

Updated Category News Views 2

stackArmor: Carving a Niche in Federal Cybersecurity Hey, not every day you wake up to find a company carving its niche in federal cybersecurity quite the way stackArmor is doing. They've recently got their hands on that elusive FedRAMP High authorization for The Armory. What's this mean in English? Well, for starters, these guys are showing they're serious about...

Continue Reading
BOC Group's Challenger Role Eye-Opener in Gartner Quadrant

Updated Category News Views 6

Cracking the Challenger Code: BOC Group's Debut Ever heard of BOC Group? If you haven’t, it’s time to pay attention. This Dublin-based outfit just muscled its way into the Challenger Quadrant of the 2026 Gartner Magic Quadrant for Digital Twin of an Organization Platforms. Not bad for its first trip to the dance. When a company crashes the scene like this, eyebrows...

Continue Reading
COFE Tech's $178M Pre-IPO Boost: Bold Move in MENA

Updated Category News Views 1

COFE Tech's Pre-IPO Raise: Scoring Big Dollars Today I'm reading this deal 'bout COFE Tech, and let me tell ya, there's more to chew over than a bowl of oatmeal. They just wrapped up a pre-IPO round at a hefty $178 million valuation. This wasn't just any ol' investment — we're talking about Wa'ed Ventures, the venture arm of Aramco, along with some heavy-hitter partners...

Continue Reading
Danielle D. Pollard Releases Game-Changing Exec Book

Updated Category News Views 0

Revolutionizing Communication Dynamics In a world where every word is scrutinized, Danielle D. Pollard's new book, Act Like a Lady, Speak Like a Wolf, arrives like a jolt of caffeine on a sleepy morning. With decades of engineering know-how and corporate grit, Pollard serves up a no-frills strategy to conquer the communication game, especially designed for women fighting...

Continue Reading
Veteran Suicide Prevention: The Urgency Behind CVN's Push

Updated Category News Views 0

Veteran suicide is a crisis staring us square in the face, with rates 60% higher than the general population. It's a grim reminder that the mental toll on those who've served is a deep chasm hard to bridge. Cohen Veterans Network (CVN) is stepping up to the plate with a new campaign dubbed 'Ask Anyway: Conversations to Save a Life'. This isn't just any awareness...

Continue Reading

Top 5 Most Recently Viewed Articles

Dillard's, Inc. Financial Overview: Q3 and Yearly Insights

Updated Category News Views 332

Insights into Dillard's, Inc. Financial Performance Dillard's, Inc. (NYSE: DDS) has recently disclosed its operating results for the 13 and 39 weeks ending on a notable date. The retail landscape has faced challenges, which are reflected in the company’s sales data and overall performance metrics. CEO's Statement on Q3 Results William T. Dillard, II, the Chief Executive...

Continue Reading
Transforming Cannabis Consumption: The Rise of Vapes and Pre-Rolls

Updated Category News Views 84

The Evolution of Cannabis Consumption in Canada Recent equity research provides fascinating insights into the Canadian cannabis market. Analysts have observed a shift in consumer preferences, particularly noting a slowdown in the growth of recreational cannabis sales. This trend prompts questions about how consumption habits are evolving among Canadians. Current Market...

Continue Reading
Celebrating Music and Wine: The 10th Annual Festival Begins

Updated Category News Views 287

Celebrating a Milestone in Music and Wine At the heart of the Willamette Valley, the Appassionata Estate is set to host a special celebration as the 10th annual Willamette Valley Chamber Music Festival opens its doors once again. This festival is not just an event; it's a fusion of music, wine, and heartfelt community connections that folks have enjoyed for a decade. As...

Continue Reading
Transforming Data Control for Users with dFusion and VANA

Updated Category News Views 285

Empowering Users with Decentralized Data Ownership dFusion AI, in conjunction with VANA, has introduced a groundbreaking initiative known as the Private Social Lens Data Liquidity Pool (DLP). This innovative framework is set to revolutionize the way conversational data, particularly Telegram messages, is collected, validated, and monetized. This effort signifies a major...

Continue Reading
Guselkumab's Innovative Approval Revolutionizes Treatment Options

Updated Category News Views 199

Understanding the Advancement of Guselkumab Guselkumab is set to redefine treatment protocols for adults dealing with ulcerative colitis (UC) and Crohn's disease (CD), providing patients and healthcare providers with the convenience and flexibility of self-administration from the initiation of therapy. The introduction of TREMFYA® (guselkumab) allows for a fully...

Continue Reading